Assessment of T helper 17-associated cytokines in thromboangiitis obliterans

Shayan Keramat,1 Mohammad Hadi Sadeghian,1,2 Mohammad Reza Keramati,1,2 Bahare Fazeli3,4 1Hematology Department, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran; 2Pathology Department, Cancer Molecular Pathology Research Center, Mashhad University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Keramat S, Sadeghian MH, Keramati MR, Fazeli B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Thromboangiitis Obliterans Buerger’s disease Autoimmunity Interleukin 17 Interleukin 22 Interleukin 23 Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/74b632133a3a4718ba27f069d84e32ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:74b632133a3a4718ba27f069d84e32ac
record_format	dspace
spelling	oai:doaj.org-article:74b632133a3a4718ba27f069d84e32ac2021-12-02T01:40:20ZAssessment of T helper 17-associated cytokines in thromboangiitis obliterans1178-7031https://doaj.org/article/74b632133a3a4718ba27f069d84e32ac2019-09-01T00:00:00Zhttps://www.dovepress.com/assessment-of-t-helper-17-associated-cytokines-in-thromboangiitis-obli-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Shayan Keramat,1 Mohammad Hadi Sadeghian,1,2 Mohammad Reza Keramati,1,2 Bahare Fazeli3,4 1Hematology Department, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran; 2Pathology Department, Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 3Immunology Department, Immunology Research Center, Inflammation and Inflammatory Diseases Division, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 4Department of Angiology, L.Sacco Hospital, Vascular Independent Research and Education, European Organization, Milan, ItalyCorrespondence: Bahare FazeliImmunology Department, Immunology Research Center, Inflammation and Inflammatory Diseases Division, School of Medicine, Mashhad University of Medical Sciences, Pardis Campus, Azadi Sqr, Mashhad, IranTel +98 513 800 2379Fax +98 513 841 4499Email bahar.fazeli@gmail.comBackground: The management of thromboangiitis obliterans (TAO) remains a medical challenge because of its unknown etiology. It is also not known whether it is a systemic or localized disease or a type of autoimmune vasculitis.Methods: In this study, we evaluated the serum level of IL-17 and IL-23 which increase in both systemic inflammation and autoimmunity, in 60 TAO patients and 30 age- and smoking habit-matched controls. Also, IL-22, which has reported high level during infection but not in autoimmunity, was evaluated.Results: The serum levels of IL-17, IL-22 and IL-23 were significantly higher in the TAO patients in comparison with the controls (P<0.001). Notably, the serum levels of IL-17, IL-22 and IL-23 were highest in the patients with the chief complaint of chronic ulcer and lowest in the patients with gangrene (P<0.05). Also, the serum level of IL-22 was significantly higher in the anemic patients in comparison with the non-anemic patients (P=0.03).Conclusion: Owing to our findings, TAO appears more likely to be a systemic disorder rather than a localized vasculopathy. Therefore, treatment protocols based on systemic treatment of TAO patients may be more helpful than localized treatment, such as bypass surgery and endovascular procedures. Also, according to our findings regarding the high level of IL-22, the trigger of TAO development may be an infectious pathogen. However, additional research is highly recommended to investigate whether TAO is an infectious disease or an infectious-induced autoimmunity.Keywords: thromboangiitis obliterans, Buerger’s disease, autoimmunity, interleukin-17, interleukin-22, interleukin-23Keramat SSadeghian MHKeramati MRFazeli BDove Medical PressarticleThromboangiitis ObliteransBuerger’s diseaseAutoimmunityInterleukin 17Interleukin 22Interleukin 23PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 12, Pp 251-258 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Thromboangiitis Obliterans Buerger’s disease Autoimmunity Interleukin 17 Interleukin 22 Interleukin 23 Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Thromboangiitis Obliterans Buerger’s disease Autoimmunity Interleukin 17 Interleukin 22 Interleukin 23 Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Keramat S Sadeghian MH Keramati MR Fazeli B Assessment of T helper 17-associated cytokines in thromboangiitis obliterans
description	Shayan Keramat,1 Mohammad Hadi Sadeghian,1,2 Mohammad Reza Keramati,1,2 Bahare Fazeli3,4 1Hematology Department, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran; 2Pathology Department, Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 3Immunology Department, Immunology Research Center, Inflammation and Inflammatory Diseases Division, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 4Department of Angiology, L.Sacco Hospital, Vascular Independent Research and Education, European Organization, Milan, ItalyCorrespondence: Bahare FazeliImmunology Department, Immunology Research Center, Inflammation and Inflammatory Diseases Division, School of Medicine, Mashhad University of Medical Sciences, Pardis Campus, Azadi Sqr, Mashhad, IranTel +98 513 800 2379Fax +98 513 841 4499Email bahar.fazeli@gmail.comBackground: The management of thromboangiitis obliterans (TAO) remains a medical challenge because of its unknown etiology. It is also not known whether it is a systemic or localized disease or a type of autoimmune vasculitis.Methods: In this study, we evaluated the serum level of IL-17 and IL-23 which increase in both systemic inflammation and autoimmunity, in 60 TAO patients and 30 age- and smoking habit-matched controls. Also, IL-22, which has reported high level during infection but not in autoimmunity, was evaluated.Results: The serum levels of IL-17, IL-22 and IL-23 were significantly higher in the TAO patients in comparison with the controls (P<0.001). Notably, the serum levels of IL-17, IL-22 and IL-23 were highest in the patients with the chief complaint of chronic ulcer and lowest in the patients with gangrene (P<0.05). Also, the serum level of IL-22 was significantly higher in the anemic patients in comparison with the non-anemic patients (P=0.03).Conclusion: Owing to our findings, TAO appears more likely to be a systemic disorder rather than a localized vasculopathy. Therefore, treatment protocols based on systemic treatment of TAO patients may be more helpful than localized treatment, such as bypass surgery and endovascular procedures. Also, according to our findings regarding the high level of IL-22, the trigger of TAO development may be an infectious pathogen. However, additional research is highly recommended to investigate whether TAO is an infectious disease or an infectious-induced autoimmunity.Keywords: thromboangiitis obliterans, Buerger’s disease, autoimmunity, interleukin-17, interleukin-22, interleukin-23
format	article
author	Keramat S Sadeghian MH Keramati MR Fazeli B
author_facet	Keramat S Sadeghian MH Keramati MR Fazeli B
author_sort	Keramat S
title	Assessment of T helper 17-associated cytokines in thromboangiitis obliterans
title_short	Assessment of T helper 17-associated cytokines in thromboangiitis obliterans
title_full	Assessment of T helper 17-associated cytokines in thromboangiitis obliterans
title_fullStr	Assessment of T helper 17-associated cytokines in thromboangiitis obliterans
title_full_unstemmed	Assessment of T helper 17-associated cytokines in thromboangiitis obliterans
title_sort	assessment of t helper 17-associated cytokines in thromboangiitis obliterans
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/74b632133a3a4718ba27f069d84e32ac
work_keys_str_mv	AT keramats assessmentofthelper17associatedcytokinesinthromboangiitisobliterans AT sadeghianmh assessmentofthelper17associatedcytokinesinthromboangiitisobliterans AT keramatimr assessmentofthelper17associatedcytokinesinthromboangiitisobliterans AT fazelib assessmentofthelper17associatedcytokinesinthromboangiitisobliterans
_version_	1718402966474457088

Assessment of T helper 17-associated cytokines in thromboangiitis obliterans

Ejemplares similares